摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5-bromo-2-methoxy-phenyl)-naphthalene-1-yl-methanol | 475272-37-8

中文名称
——
中文别名
——
英文名称
(5-bromo-2-methoxy-phenyl)-naphthalene-1-yl-methanol
英文别名
(5-Bromo-2-methoxy-phenyl)-napthalen-1-yl-methanol;(5-bromo-2-methoxyphenyl)-naphthalen-1-ylmethanol
(5-bromo-2-methoxy-phenyl)-naphthalene-1-yl-methanol化学式
CAS
475272-37-8
化学式
C18H15BrO2
mdl
——
分子量
343.22
InChiKey
OQFRWWOOYFQUOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (5-bromo-2-methoxy-phenyl)-naphthalene-1-yl-methanol盐酸(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium tetrahydroborate 、 四(三苯基膦)钯potassium acetate三溴化硼 、 sodium carbonate 、 potassium carbonate三氟乙酸 作用下, 以 乙二醇二甲醚乙醇二氯甲烷二甲基亚砜丙酮 为溶剂, 反应 102.0h, 生成 3-(2',2''-diisobutyl-4-methoxycarbonylmethoxy-3-naphthalen-1-ylmethyl-[1,1':4',1'']-terphenyl-4''-yl)propionic acid methyl ester
    参考文献:
    名称:
    Development of a Potent Bcl-xL Antagonist Based on α-Helix Mimicry
    摘要:
    The rational design of low-molecular weight ligands that disrupt protein-protein interactions is still a challenging goal in medicinal chemistry. Our approach to this problem involves the design of molecular scaffolds that mimic the surface functionality projected along one face of an alpha-helix. Using a terphenyl scaffold, which in a staggered conformation closely reproduces the projection of functionality on the surface of an alpha-helix, we designed mimics of the pro-apoptotic alpha-helical Bak-peptide as inhibitors of the Bak/Bcl-xL interaction. This led to the development of a potent Bcl-xL antagonist (KD = 114 nM), whose binding affinity for Bcl-xL was assessed by a fluorescence polarization assay. To determine the binding site of the developed inhibitor we used docking studies and an HSQC-NMR experiment with 15N-labeled Bcl-xL protein. These studies suggest that the inhibitor is binding in the same hydrophobic cleft as the Bak- and Bad-peptides.
    DOI:
    10.1021/ja026861k
  • 作为产物:
    描述:
    1-溴代萘5-溴-2-甲氧基苯甲醛正丁基锂 作用下, 以 四氢呋喃 、 Petroleum ether 为溶剂, 反应 1.0h, 以88.15%的产率得到(5-bromo-2-methoxy-phenyl)-naphthalene-1-yl-methanol
    参考文献:
    名称:
    Development of a Potent Bcl-xL Antagonist Based on α-Helix Mimicry
    摘要:
    The rational design of low-molecular weight ligands that disrupt protein-protein interactions is still a challenging goal in medicinal chemistry. Our approach to this problem involves the design of molecular scaffolds that mimic the surface functionality projected along one face of an alpha-helix. Using a terphenyl scaffold, which in a staggered conformation closely reproduces the projection of functionality on the surface of an alpha-helix, we designed mimics of the pro-apoptotic alpha-helical Bak-peptide as inhibitors of the Bak/Bcl-xL interaction. This led to the development of a potent Bcl-xL antagonist (KD = 114 nM), whose binding affinity for Bcl-xL was assessed by a fluorescence polarization assay. To determine the binding site of the developed inhibitor we used docking studies and an HSQC-NMR experiment with 15N-labeled Bcl-xL protein. These studies suggest that the inhibitor is binding in the same hydrophobic cleft as the Bak- and Bad-peptides.
    DOI:
    10.1021/ja026861k
点击查看最新优质反应信息

文献信息

  • Proteomimetic compounds and methods
    申请人:——
    公开号:US20030008882A1
    公开(公告)日:2003-01-09
    The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.
    本发明涉及具有蛋白质拟态作用的化合物和药物组合物,以及抑制α-螺旋蛋白与另一蛋白或结合位点相互作用的方法。治疗通过α-螺旋蛋白与其结合位点之间相互作用调节的疾病或病况的方法是本发明的其他方面。
  • EP1408986A4
    申请人:——
    公开号:EP1408986A4
    公开(公告)日:2006-01-11
  • PROTEOMIMETIC COMPOUNDS AND METHODS
    申请人:Yale University
    公开号:EP1408986B1
    公开(公告)日:2008-09-24
  • US6858600B2
    申请人:——
    公开号:US6858600B2
    公开(公告)日:2005-02-22
  • US7312246B2
    申请人:——
    公开号:US7312246B2
    公开(公告)日:2007-12-25
查看更多